Responses
Regular and young investigator award abstracts
Checkpoint blockade therapy
256 Single-agent zalifrelimab (anti-CTLA-4) shows clinical benefit in rare tumors – case report from phase 2 study (NCT03104699)
Compose a Response to This Article
Other responses
No responses have been published for this article.
